Compartir
systemic radiotherapy with monoclonal antibodies: options and problems (en Inglés)
Michael Wannenmacher
(Ilustrado por)
·
Marie-Luise Sautter-Bihl
(Ilustrado por)
·
Heiner Bihl
(Ilustrado por)
·
Springer
· Tapa Blanda
systemic radiotherapy with monoclonal antibodies: options and problems (en Inglés) - Sautter-Bihl, Marie-Luise ; Bihl, Heiner ; Wannenmacher, Michael
$ 152.140
$ 253.560
Ahorras: $ 101.420
Elige la lista en la que quieres agregar tu producto o crea una nueva lista
✓ Producto agregado correctamente a la lista de deseos.
Ir a Mis Listas
Origen: Estados Unidos
(Costos de importación incluídos en el precio)
Se enviará desde nuestra bodega entre el
Martes 28 de Mayo y el
Viernes 07 de Junio.
Lo recibirás en cualquier lugar de Chile entre 1 y 3 días hábiles luego del envío.
Reseña del libro "systemic radiotherapy with monoclonal antibodies: options and problems (en Inglés)"
Almost a century ago Paul Ehrlich introduced the "magic bullet" concept of targeting therapeutic agents to specific tissues in order to reduce systemic toxicity. Due to the advances in hybridoma technology in the 1980s, monoclonal antibodies (MAbs) with their exquisite affinity to tumor antigens have become powerful tools in the treatment of cancer, especially when linked to therapeutic agents such as radionuclides, drugs, toxins, or enzymes. It can now be expected that such agents will lead to new cancer treatments with high therapeutic success rates. However, there are major problems in developing this therapeutic concept to a routine treatment modality. This is partly due to factors such as heterogenous distribution of tumor antigens, insufficient blood supply of tumors, high interstitial pressure, and the large interstitial space that antibodies have to traverse. This book is focused on the development in radio immunotherapy (RIT) using radio- labeled monoclonal antibodies as tumoritoxic agents. This area of research has attracted the interest of clinicians and scientists from many different disciplines. It is now clear that the full potential of RIT can only be realized through the concerted efforts of laboratory scientists (molecular biologists, cell physiologists, chemists, radiation physicists, and biologists) and cancer clinicians in nuclear medicine, radiooncology, and internal oncology.
